查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1372730

促紅血球生成素刺激劑市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按類型、應用和地區、競爭細分

Erythropoietin Stimulating Agents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Type, Application, and By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 172 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022年，全球促紅血球生成素（ESA）市場估值達到74.5億美元，並有望在預測期內實現顯著成長，預計到2028年年複合成長率（CAGR）為 8.14%。EPO）是一種主要由腎小管產生的糖​​蛋白造血激素，在指導和調節骨髓內紅血球生成過程中發揮至關重要的作用。促紅血球生成素刺激劑 (ESA) 具有加速紅血球增殖的能力。這些藥物被推薦用於治療化療、愛滋病毒、慢性腎衰竭以及挑戰性手術過程中紅血球計數低引起的貧血。

貧血是一種常見的疾病，與各種潛在疾病有關，如慢性腎臟病 (CKD)、癌症、愛滋病毒/愛滋病和發炎性疾病。這些疾病的普遍性增加了對 ESA 療法的需求，以有效控制貧血。此外，全球人口正在老化，老年人更容易患上導致貧血的疾病。隨著老年人口的持續成長，對 ESA 治療的需求可能會增加。

癌症診斷和治療的進步導致越來越多的癌症患者接受化療和放射治療。這些治療可能引發貧血，從而增加對 ESA 藥物的需求。醫學協會和醫療保健組織發布的臨床指南經常推薦 ESA 治療來控制特定患者群體的貧血，從而影響治療決策。美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等監管機構在批准 ESA 產品用於各種適應症方面發揮關鍵作用，從而擴大了其使用範圍。患者倡導團體和組織在提高對貧血相關疾病的認知和倡導改善 ESA 治療的可及性方面發揮著至關重要的作用，從而增加了患者的需求。 ESA 產品生物相似藥的推出引入了市場競爭，有可能降低治療成本並擴大這些療法的使用範圍。

市場概況
預測期 2024-2028
2022 年市場規模 74.5億美元
2028 年市場規模 119.4億美元
2023-2028 年年複合成長率 8.14%
成長最快的細分市場 癌症
最大的市場 北美洲

主要市場促進因素

腫瘤學的進展

化療引起的貧血是癌症治療的常見副作用，導致疲勞和生活品質下降。諸如 Epoetin Alfa 和 Darbepoetin Alfa 等 ESA 已被用於管理 CIA。腫瘤學的進步導致了更有效和更有針對性的化療方案的開發，這可能會減輕與治療相關的貧血的嚴重程度。從歷史上看，ESA 一直與安全問題有關，尤其是癌症患者心血管事件風險增加。腫瘤學研究的進展有助於更好地了解 ESA 的安全性，並確定可能受益於 ESA 治療同時將風險降至最低的患者亞群。腫瘤基因組學和個人化醫療的進步帶來了更個人化的癌症治療計劃。這可以包括根據患者的基因譜和潛在癌症類型量身定做 ESA 治療，最佳化治療結果，同時最大限度地降低風險。

人口老化的成長

由於多種因素，包括慢性疾病、營養缺乏和骨髓功能下降，貧血在老年人中更為常見。隨著年齡的成長，患貧血或原有貧血惡化的風險也會增加。老年人更有可能患有慢性健康問題，例如慢性腎臟病、癌症和發炎性疾病。其中許多情況可能導致貧血。 ESA 通常用於治療老年患者與這些慢性疾病相關的貧血。老化會導致人體自然產生的促紅血球生成素下降，而促紅血球生成素則是刺激骨髓中紅血球生成的荷爾蒙。這可能會導致有效應對貧血的能力下降，從而使 ESA 成為一種有價值的治療選擇。貧血會導致疲勞、虛弱和呼吸急促等症狀，對老年人的生活品質產生負面影響。 ESA 可以幫助緩解這些症狀並改善整體健康狀況，使其成為老年患者理想的治療選擇。

對老年人來說，減少輸血需求通常是治療的目標。 ESA 可用於提高血紅素水平，減少老年患者的輸血依賴性和相關風險。醫學指南經常建議使用 ESA 來治療老年人貧血，特別是當貧血與特定慢性病有關時。醫療保健提供者在治療老年患者時可以遵循這些指南。隨著人口老化，人們越來越關注改善老年人的整體健康和福祉。管理貧血是老年人口支持性護理的一部分，與提高他們的生活品質的努力一致。在許多已開發國家，老年人可以使用可為他們提供 ESA 治療的醫療保健系統。這種可近性有助於增加老齡化人口對 ESA 治療的需求。隨著醫療保健支出隨著人口老化而增加，資源被分配用於滿足老年人的醫療保健需求，包括透過 ESA 管理貧血。這項因素將加速全球促紅血球生成素刺激劑市場的需求。

貧血相關疾病的盛行率不斷增加

貧血是一種以紅血球或血紅蛋白缺乏為特徵的疾病，可導致疲勞、虛弱和血液攜氧能力降低等症狀。貧血是全世界常見的健康問題，影響數百萬人。在某些人群中，該疾病的盛行率特別高，包括患有慢性腎臟病 (CKD)、癌症、愛滋病毒/愛滋病和發炎性疾病等慢性疾病的個體。貧血是 CKD（慢性腎臟病）的一種眾所周知的併發症，尤其是在晚期。由於人口老化以及糖尿病和高血壓發病率上升等因素的推動，CKD 盛行率不斷增加，因此越來越需要 ESA 治療來控制 CKD 患者的貧血。癌症和癌症治療會導致貧血，這種情況稱為化療引起的貧血 (CIA)。全球癌症盛行率呈上升趨勢，隨著越來越多的人接受癌症治療，對 ESA 管理 CIA 的需求也在增加。由於骨髓功能下降、營養缺乏和慢性疾病等因素，老年人更容易患貧血。隨著全球人口持續老化，年齡相關性貧血的盛行率預計將上升，從而增加對 ESA 治療的需求。類風濕性關節炎和發炎性腸道疾病等疾病會導致慢性炎症，進而導致貧血。這些發炎性疾病的盛行率很高，ESA 治療對於控制受影響患者的貧血可能是必要的。

貧血是愛滋病毒/愛滋病感染者常見的併發症。隨著全球愛滋病毒/愛滋病感染者人數持續成長，對 ESA 療法來解決愛滋病毒相關貧血症的需求仍然很大。某些營養缺乏，如鐵、維生素 B12 和葉酸缺乏，可導致貧血。雖然營養缺乏可以透過補充和飲食改變來解決，但有些人可能仍然需要 ESA，特別是如果營養缺乏嚴重或持續存在。由於腎臟產生紅血球生成素的能力喪失，接受血液透析治療末期腎病變的患者常會出現貧血。血液透析依賴患者的普遍存在增加了對 ESA 治療的需求。醫學診斷的進步和對貧血相關疾病認知的提高使得貧血診斷更加準確和早期。這反過來又推動了對包括 ESA 在內的適當治療的需求。醫學協會發布的臨床實踐指南通常建議使用 ESA 來治療特定患者群體的貧血。這些指南影響治療決策並促進對 ESA 的需求。這項因素將加速全球促紅血球生成素刺激劑市場的需求。

主要市場挑戰

專利到期

當 ESA 藥物的專利到期時，其他製藥公司可以開發和銷售這些藥物的學名藥或生物學名藥。這種競爭的加劇可能會導致 ESA 價格下降，因為學名藥或生物學名藥產品的價格通常低於原始品牌版本。專利到期可能會導致原始 ESA 製造商的市場佔有率受到侵蝕。學名藥和生物相似藥可以佔領很大一部分市場，特別是如果它們的價格更具競爭力的話。學名藥和生物學名藥競爭對手的進入通常會導致 ESA 市場的價格下降。較低的價格可能會影響原始 ESA 製造商的收入和盈利能力。 ESA藥物歷來都是製藥公司的高收入產品，其專利到期可能會導致這些公司的銷售收入下降。 ESA 市場可能會因多個提供類似產品的學名藥和生物相似藥競爭對手而變得碎片化。這種分散化可能會導致定價壓力和競爭加劇。專利到期帶來的競爭壓力可能會降低原始製造商投資 ESA 產品進一步研發的動力，從而可能減緩該領域的創新。專利到期可能會影響市場進入和定價策略。製造商可能需要調整其定價和存取策略以保持市場競爭力。雖然專利到期可以透過降低 ESA 治療的成本來使醫療保健系統受益，但它們也可能在確保患者安全和生物相似藥產品的適當使用方面帶來挑戰。

改變治療模式

隨著醫學知識的進步，可能會出現新的治療方式，以減少對 ESA 的依賴。例如，慢性腎臟病（CKD）或癌症相關貧血的治療進展可能涉及替代方法，例如改善營養、補充鐵劑或解決貧血根本原因的標靶治療。不斷發展的治療模式可能會導致對 ESA 風險效益狀況的重新評估。例如，對 ESA 安全性的擔憂（例如心血管事件風險增加）導致指南和建議發生變化。在某些情況下，醫療保健提供者在開立 ESA 處方時可能會變得更加謹慎。個人化醫學和遺傳學研究可以製定適合個別患者的治療計劃。在某些情況下，如果可以透過其他方式控制貧血或替代治療對特定患者情況更有效，這可能會導致 ESA 的需求減少。不斷發展的治療範式可能會強調多模式或聯合療法。在某些情況下，ESA 可能仍然發揮作用，但它們可以與其他治療結合使用，例如補充鐵劑或具有不同作用機制的紅血球生成刺激劑。治療範式的改變通常會考慮成本效益。醫療保健系統可能會選擇更具成本效益的治療策略，這可能會影響 ESA 的利用。醫學協會發布的臨床實踐指南可能會不斷發展，以反映治療範式的變化和新治療方案的可用性。這些指南影響治療決策並可能影響 ESA 的利用。

主要市場趨勢

轉向依泊汀生物相似藥

生物相似藥是與已核准的參考生物製劑（在本例中為依泊汀）高度相似的生物藥物，在安全性和有效性方面沒有臨床意義的差異。生物相似藥的開發和批准在 ESA 市場中意義重大。依泊汀生物相似藥的價格通常低於原品牌依泊汀產品。這種成本優勢使它們成為醫療保健系統和提供者在保持護理品質的同時控制醫療保健支出的有吸引力的選擇。依泊汀生物相似藥的推出加劇了 ESA 市場的競爭。這種競爭可以降低價格並增加患者接受 ESA 治療的機會。 Epoetin 生物相似藥的上市有可能擴大 ESA 治療的可及性，特別是在出於成本考慮而無法獲得原始品牌產品的地區或醫療保健系統。採用依泊汀生物相似藥可以為患者和醫療保健提供者節省大量醫療成本，這在預算有限的地區尤其重要。美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等監管機構已根據嚴格的可比性評估批准了依泊汀生物相似藥。這項監管批准增強了人們對其安全性和有效性的信心。隨著時間的推移，醫療保健提供者和患者越來越接受生物相似藥，因為他們獲得了更多的使用經驗，而現實世界的證據支持其有效性和安全性。

細分市場洞察

類型洞察

2022 年，全球促紅血球生成素刺激劑市場最大佔有率由 Epoetin Alfa 部門在預測期內佔據，預計未來幾年將繼續擴大。 Epoetin Alfa 以各種品牌銷售，是首批推向市場的 ESA 產品之一。它的早期進入使其能夠站穩腳跟並在醫療保健提供者之間建立信任。阿爾法依泊汀在臨床實務上有著悠久的使用歷史。醫療保健專業人士熟悉其安全性和有效性，這有助於其廣泛採用。醫學協會的臨床指南和建議通常將阿法依泊汀作為治療特定患者群體貧血的首選或標準治療選擇。一些醫生可能根據他們的臨床經驗和對產品的熟悉程度對依泊汀阿爾法產生了偏好。

應用洞察

2022年，全球促紅血球生成素刺激劑市場在預測期內以癌症應用領域為主，預計未來幾年將持續擴大。癌症患者經常接受化療，這可能導致化療引起的貧血。 ESA 通常用於治療這些患者的貧血。化療引起的貧血是癌症治療的常見副作用，而解決這個問題對於改善患者的生活品質和治療結果至關重要。癌症是一種普遍存在的疾病，其盛行率在全球範圍內一直在穩步上升。隨著癌症患者數量的增加，對 ESA 等治療貧血的支持療法的需求也在增加。貧血會導致癌症患者疲勞、虛弱和生活品質下降。 ESA 有助於提高血紅蛋白水平、緩解貧血相關症狀並改善患者的整體健康狀況，使他們能夠更好地耐受癌症治療。

區域洞察

北美地區在2022年全球促紅血球生成素刺激劑市場中佔據主導地位。北美地區，特別是美國和加拿大，擁有發達的醫療基礎設施，擁有先進的醫療設施、高標準的護理和便利的醫療服務。該基礎設施有利於 ESA 療法的處方、管理和監測。慢性腎臟病 (CKD) 和癌症是需要 ESA 治療來控制貧血的兩種最常見疾病。北美的 CKD 和癌症盛行率相對較高，導致大量患者需要 ESA 治療。美國是許多製藥和生物技術公司的所在地，有能力開發、製造和分銷 ESA 產品。這些公司擁有支持該地區 ESA 治療的資源和專業知識。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：COVID-19 對全球飼料植物源市場的影響

第 5 章：客戶之聲

第 6 章：全球促紅血球生成素市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型（依泊汀阿爾法、依泊汀貝塔、達貝泊汀阿爾法和其他類型）
    • 按應用（癌症、腎臟疾病、抗病毒治療、神經疾病和其他應用）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 7 章：亞太地區促紅血球生成素市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按應用
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國促紅血球生成素
    • 印度促紅血球生成素刺激劑
    • 澳洲促紅血球生成素劑
    • 日本促紅血球生成劑
    • 韓國促紅血球生成素劑

第 8 章：歐洲促紅血球生成素市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按應用
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 9 章：北美促紅血球生成素市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按應用
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 10 章：南美洲促紅血球生成素市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按應用
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章：中東和非洲促紅血球生成素市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按應用
    • 按國家/地區
  • MEA：國家分析
    • 南非促紅血球生成素刺激劑
    • 沙烏地阿拉伯 促紅血球生成素刺激劑
    • 阿拉伯聯合大公國促紅血球生成素刺激劑

第 12 章：市場動態

  • 促進要素
  • 挑戰

第 13 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 14 章：全球促紅血球生成素刺激劑市場：SWOT 分析

第 15 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第 16 章：大環境分析

第17章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（上市公司）
  • 最近的發展
  • SWOT分析
    • Amgen Inc.
    • Biocon Limited
    • Celltrion Inc.
    • F. Hoffmann-La Roche Ltd
    • Intas Pharmaceuticals Ltd
    • Johnson and Johnson
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd
    • Thermo Fisher Scientific
    • LG Lifesciences, Ltd
    • Novartis AG(Sandoz)
    • Panacea Biotec Ltd

第 18 章：策略建議

第 19 章：關於我們與免責聲明

簡介目錄
Product Code: 16145

In 2022, the Global Erythropoietin Stimulating Agents (ESAs) Market reached a valuation of USD 7.45 billion and is poised to experience remarkable growth in the forecasted period, with an anticipated Compound Annual Growth Rate (CAGR) of 8.14% through 2028. Endogenous erythropoietin (EPO), a glycoprotein hematopoietic hormone primarily produced by renal tubules, plays a crucial role in directing and regulating the erythropoiesis process within the bone marrow. Erythropoietin Stimulating Agents (ESAs) have the capacity to accelerate the proliferation of red blood cells. These medications are recommended for the treatment of anemia induced by chemotherapy, HIV, chronic kidney failure, and low red blood cell counts during challenging surgical procedures.

Anemia is a common medical condition associated with various underlying diseases such as chronic kidney disease (CKD), cancer, HIV/AIDS, and inflammatory disorders. The prevalence of these conditions contributes to the demand for ESA therapies to effectively manage anemia. Furthermore, the global population is aging, and elderly individuals are more susceptible to conditions that can lead to anemia. As the elderly population continues to grow, there is a potential increase in demand for ESA treatments.

Advancements in cancer diagnosis and treatment have resulted in a higher number of cancer patients undergoing chemotherapy and radiation therapy. These treatments can trigger anemia, driving a greater need for ESA drugs. Clinical guidelines issued by medical associations and healthcare organizations often recommend ESA therapy for managing anemia in specific patient populations, influencing treatment decisions. Regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play pivotal roles in approving ESA products for various indications, thereby expanding their utilization. Patient advocacy groups and organizations play a vital role in raising awareness about anemia-related conditions and advocating for improved access to ESA therapies, leading to increased patient demand. The introduction of biosimilar versions of ESA products has introduced competition in the market, potentially reducing treatment costs and expanding access to these therapies.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 7.45 Billion
Market Size 2028USD 11.94 Billion
CAGR 2023-20288.14%
Fastest Growing SegmentCancer
Largest MarketNorth America

Key Market Drivers

Advancements in Oncology

Chemotherapy-induced anemia is a common side effect of cancer treatment, leading to fatigue and reduced quality of life. ESAs like Epoetin Alfa and Darbepoetin Alfa have been used to manage CIA. Advancements in oncology have led to the development of more effective and targeted chemotherapy regimens, which may reduce the severity of anemia associated with treatment. Historically, ESAs have been associated with safety concerns, particularly an increased risk of cardiovascular events in cancer patients. Advances in oncology research have contributed to a better understanding of the safety profiles of ESAs and the identification of patient subgroups that may benefit from ESA therapy while minimizing risks. Advances in oncogenomics and personalized medicine have led to more individualized cancer treatment plans. This can include tailoring ESA therapy based on a patient's genetic profile and underlying cancer type, optimizing treatment outcomes while minimizing risks.

Oncology treatment guidelines from organizations like the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) provide recommendations on the use of ESAs in cancer patients. These guidelines are updated regularly to reflect the latest research findings and advancements in cancer care. Targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, have become increasingly important in oncology. These therapies are designed to specifically target cancer cells while sparing healthy ones. As a result, some targeted therapies may have a reduced impact on red blood cell production and anemia, potentially reducing the need for ESAs in certain cases. Oncologists may explore combinations of treatments to improve cancer outcomes. The use of ESAs in conjunction with other supportive care measures, such as blood transfusions or iron supplementation, can be tailored to the specific needs of cancer patients. Ongoing clinical trials in oncology often include investigations into the use of ESAs in combination with new cancer therapies. These trials aim to identify optimal treatment strategies and improve patient outcomes. The development and approval of biosimilar versions of ESAs have introduced more cost-effective alternatives to the market. Biosimilars may play a role in reducing the economic burden of ESA therapy in oncology. Advancements in oncology have led to improved strategies for monitoring patients receiving ESA therapy, including regular assessment of hemoglobin levels and cardiovascular risk factors. This allows for early intervention and risk mitigation. This factor will help in the development of Global Erythropoietin Stimulating Agents Market.

Growth in Aging Population

Anemia is more common in older adults due to various factors, including chronic diseases, nutritional deficiencies, and reduced bone marrow function. As people age, their risk of developing anemia or experiencing a worsening of pre-existing anemia increases. Older adults are more likely to have chronic health conditions such as chronic kidney disease, cancer, and inflammatory disorders. Many of these conditions can lead to anemia. ESAs are commonly used to manage anemia associated with these chronic diseases in older patients. Aging can lead to a decline in the body's natural production of erythropoietin, the hormone that stimulates the production of red blood cells in the bone marrow. This can result in a decreased ability to respond to anemia effectively, making ESAs a valuable treatment option. Anemia can cause symptoms such as fatigue, weakness, and shortness of breath, negatively impacting the quality of life in older adults. ESAs can help alleviate these symptoms and improve overall well-being, making them a desirable treatment option for elderly patients.

In older adults, reducing the need for blood transfusions is often a goal of treatment. ESAs can be used to raise hemoglobin levels, reducing transfusion dependence and associated risks in elderly patients. Medical guidelines often recommend the use of ESAs for managing anemia in older adults, particularly when anemia is related to specific chronic conditions. Healthcare providers may follow these guidelines when treating elderly patients. As populations age, there is an increased focus on improving the overall health and well-being of older adults. Managing anemia is part of supportive care for the aging population, aligning with efforts to enhance their quality of life. In many developed countries, older adults have access to healthcare systems that can provide them with ESA treatments. This accessibility contributes to the demand for ESA therapy among the aging population. As healthcare expenditure increases with aging populations, resources are allocated to addressing the healthcare needs of older adults, including the management of anemia with ESAs. This factor will pace up the demand of Global Erythropoietin Stimulating Agents Market.

Increasing Prevalence of Anemia-Related Conditions

Anemia is a condition characterized by a deficiency of red blood cells or hemoglobin, which can lead to symptoms such as fatigue, weakness, and reduced oxygen-carrying capacity in the blood. Anemia is a common health issue worldwide, affecting millions of people. The prevalence is particularly high in certain populations, including individuals with chronic diseases such as chronic kidney disease (CKD), cancer, HIV/AIDS, and inflammatory disorders. Anemia is a well-recognized complication of CKD (Chronic Kidney Disease), especially in advanced stages. As the prevalence of CKD increases, driven by factors like aging populations and rising rates of diabetes and hypertension, there is a growing need for ESA therapy to manage anemia in CKD patients. Cancer and cancer treatments can lead to anemia, a condition known as chemotherapy-induced anemia (CIA). The prevalence of cancer is on the rise globally, and as more individuals undergo cancer treatments, the demand for ESAs to manage CIA also increases. Older adults are more susceptible to anemia due to factors such as reduced bone marrow function, nutritional deficiencies, and chronic illnesses. As the global population continues to age, the prevalence of age-related anemia is expected to rise, contributing to the demand for ESA therapy. Conditions like rheumatoid arthritis and inflammatory bowel disease can lead to chronic inflammation, which can contribute to anemia. The prevalence of these inflammatory disorders is significant, and ESA therapy may be necessary for managing anemia in affected patients.

Anemia is a common complication in individuals living with HIV/AIDS. As the global population living with HIV/AIDS continues to grow, the demand for ESA therapy to address HIV-related anemia remains substantial. Certain nutritional deficiencies, such as iron, vitamin B12, and folate deficiencies, can lead to anemia. Although nutritional deficiencies can be addressed with supplementation and dietary changes, some individuals may still require ESAs, especially if the deficiency is severe or persistent. Patients on hemodialysis for end-stage renal disease often experience anemia due to the loss of erythropoietin-producing capacity in the kidneys. The prevalence of hemodialysis-dependent patients contributes to the demand for ESA therapy. Advances in medical diagnostics and increased awareness of anemia-related conditions have led to more accurate and early diagnosis of anemia. This, in turn, drives the demand for appropriate treatments, including ESAs. Clinical practice guidelines issued by medical associations often recommend the use of ESAs for managing anemia in specific patient populations. These guidelines influence treatment decisions and contribute to the demand for ESAs. This factor will accelerate the demand of Global Erythropoietin Stimulating Agents Market.

Key Market Challenges

Patent Expirations

When the patents for ESA drugs expire, it allows other pharmaceutical companies to develop and market generic or biosimilar versions of these drugs. This increased competition can lead to a reduction in the price of ESAs as generic or biosimilar products are typically priced lower than the original branded versions. The expiration of patents can result in the erosion of market share for the original ESA manufacturers. Generic and biosimilar versions can capture a significant portion of the market, particularly if they are more competitively priced. The entry of generic and biosimilar competitors often leads to price erosion in the ESA market. Lower prices can impact the revenue and profitability of the original ESA manufacturers. ESA drugs have historically been high-revenue products for pharmaceutical companies, and their patent expirations can lead to a decline in sales revenue for these companies. The ESA market can become fragmented with multiple generic and biosimilar competitors offering similar products. This fragmentation can lead to pricing pressures and increased competition. The competitive pressure resulting from patent expirations may reduce the incentive for original manufacturers to invest in further research and development for ESA products, potentially slowing down innovation in the field. Patent expirations can impact market access and pricing strategies. Manufacturers may need to adjust their pricing and access strategies to remain competitive in the market. While patent expirations can benefit healthcare systems by reducing the cost of ESA therapy, they can also pose challenges in terms of ensuring patient safety and the appropriate use of biosimilar products.

Changing Treatment Paradigms

As medical knowledge advances, new treatment modalities may emerge that reduce the reliance on ESAs. For example, advances in the management of chronic kidney disease (CKD) or cancer-related anemia might involve alternative approaches such as improved nutrition, iron supplementation, or targeted therapies that address the underlying causes of anemia. Evolving treatment paradigms may lead to a reevaluation of the risk-benefit profile of ESAs. For instance, concerns about ESA safety, such as an increased risk of cardiovascular events, have led to changes in guidelines and recommendations. Healthcare providers may become more cautious in prescribing ESAs in certain situations. Personalized medicine and genetics research can lead to the development of treatment plans tailored to individual patients. In some cases, this may result in a reduced need for ESAs if anemia can be managed through other means or if alternative treatments are more effective for specific patient profiles. Evolving treatment paradigms may emphasize multimodal or combination therapies. In some cases, ESAs may still play a role, but they may be used in conjunction with other treatments, such as iron supplementation or erythropoiesis-stimulating agents with different mechanisms of action. Changes in treatment paradigms often consider cost-effectiveness considerations. Healthcare systems may opt for treatment strategies that are more cost-effective, which could affect the utilization of ESAs. Clinical practice guidelines issued by medical associations may evolve to reflect changes in treatment paradigms and the availability of new treatment options. These guidelines influence treatment decisions and can impact ESA utilization.

Key Market Trends

Shift Toward Epoetin Biosimilars

Biosimilars are biologic drugs that are highly like an already approved reference biologic (in this case, Epoetin) with no clinically meaningful differences in terms of safety and efficacy. The development and approval of biosimilars have been significant in the ESA market. Epoetin biosimilars are often priced lower than the original branded Epoetin products. This cost advantage makes them an attractive option for healthcare systems and providers looking to contain healthcare expenditures while maintaining the quality of care. The introduction of biosimilar versions of Epoetin has increased competition in the ESA market. This competition can lead to reduced prices and increased accessibility of ESA therapies for patients. The availability of Epoetin biosimilars has the potential to expand access to ESA therapy, particularly in regions or healthcare systems where cost considerations may have limited access to the original branded products. The adoption of Epoetin biosimilars can result in substantial healthcare cost savings for both patients and healthcare providers, which is particularly important in regions with budget constraints. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have approved Epoetin biosimilars based on rigorous comparability assessments. This regulatory approval has increased confidence in their safety and efficacy. Over time, healthcare providers and patients have become more accepting of biosimilars as they gain more experience with their use and as real-world evidence supports their effectiveness and safety.

Segmental Insights

Type Insights

In 2022, the Global Erythropoietin Stimulating Agents Market largest share was held by Epoetin Alfa segment in the forecast period and is predicted to continue expanding over the coming years. Epoetin Alfa, marketed under various brand names, was one of the first ESA products to be introduced to the market. Its early entry allowed it to establish a strong foothold and build trust among healthcare providers. Epoetin Alfa had a long history of use in clinical practice. Healthcare professionals were familiar with its safety and efficacy profile, which contributed to its widespread adoption. Clinical guidelines and recommendations from medical associations often included Epoetin Alfa as a preferred or standard treatment option for managing anemia in specific patient populations. Some physicians may have developed preferences for Epoetin Alfa based on their clinical experiences and familiarity with the product.

Application Insights

In 2022, the Global Erythropoietin Stimulating Agents Market was dominated by Cancer Application segment in the forecast period and is predicted to continue expanding over the coming years. Cancer patients often undergo chemotherapy, which can lead to a condition known as chemotherapy-induced anemia. ESAs are commonly prescribed to manage anemia in these patients. Chemotherapy-induced anemia is a prevalent side effect of cancer treatment, and addressing it is crucial for improving patients' quality of life and treatment outcomes. Cancer is a widespread disease, and its prevalence has been steadily increasing globally. As the number of cancer patients grows, so does the demand for supportive therapies like ESAs to manage anemia. Anemia can lead to fatigue, weakness, and reduced quality of life in cancer patients. ESAs help raise hemoglobin levels, alleviate anemia-related symptoms, and improve patients' overall well-being, allowing them to better tolerate cancer treatments.

Regional Insights

The North America region dominates the Global Erythropoietin Stimulating Agents Market in 2022. North America, particularly the United States and Canada, boasts a well-developed healthcare infrastructure with advanced medical facilities, a high standard of care, and easy access to healthcare services. This infrastructure facilitates the prescription, administration, and monitoring of ESA therapies. Chronic kidney disease (CKD) and cancer are two of the most common conditions necessitating ESA treatment to manage anemia. North America has a relatively high prevalence of both CKD and cancer, leading to a significant patient population requiring ESA therapy. The United States is home to many pharmaceutical and biotechnology companies with the capability to develop, manufacture, and distribute ESA products. These companies have the resources and expertise to support ESA therapy in the region.

Key Market Players

  • Amgen Inc.
  • Biocon Limited
  • Celltrion Inc.
  • F. Hoffmann-La Roche Ltd
  • Intas Pharmaceuticals Ltd
  • Johnson and Johnson
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • Thermo Fisher Scientific
  • LG Lifesciences, Ltd
  • Novartis AG(Sandoz)
  • Panacea Biotec Ltd

Report Scope:

In this report, the Global Erythropoietin Stimulating Agents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Erythropoietin Stimulating Agents Market, By Type:

  • Epoetin Alfa
  • Epoetin Beta
  • Darbepoetin Alfa
  • Other Types

Erythropoietin Stimulating Agents Market, By Application:

  • Cancer
  • Renal Disorders
  • Anti-retroviral Treatment
  • Neural Diseases
  • Other Applications

Global Erythropoietin Stimulating Agents Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Erythropoietin Stimulating Agents Market.

Available Customizations:

  • Global Erythropoietin Stimulating Agents Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Feed Phytogenic Market

5. Voice of Customer

6. Global Erythropoietin Stimulating Agents Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type (Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, And Other Types)
    • 6.2.2. By Application (Cancer, Renal Disorders, Anti-retroviral Treatment, Neural Diseases, and Other Applications)
    • 6.2.3. By Region
    • 6.2.4. By Company (2022)
  • 6.3. Market Map

7. Asia Pacific Erythropoietin Stimulating Agents Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Asia Pacific: Country Analysis
    • 7.3.1. China Erythropoietin Stimulating Agents Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. India Erythropoietin Stimulating Agents Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. Australia Erythropoietin Stimulating Agents Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Japan Erythropoietin Stimulating Agents Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. South Korea Erythropoietin Stimulating Agents Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Europe Erythropoietin Stimulating Agents Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Erythropoietin Stimulating Agents Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. Germany Erythropoietin Stimulating Agents Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Spain Erythropoietin Stimulating Agents Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. Italy Erythropoietin Stimulating Agents Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. United Kingdom Erythropoietin Stimulating Agents Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. North America Erythropoietin Stimulating Agents Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Erythropoietin Stimulating Agents Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. Mexico Erythropoietin Stimulating Agents Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. Canada Erythropoietin Stimulating Agents Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America Erythropoietin Stimulating Agents Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Erythropoietin Stimulating Agents Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Argentina Erythropoietin Stimulating Agents Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Colombia Erythropoietin Stimulating Agents Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Middle East and Africa Erythropoietin Stimulating Agents Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. By Application
    • 11.2.3. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Erythropoietin Stimulating Agents Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Application
    • 11.3.2. Saudi Arabia Erythropoietin Stimulating Agents Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Application
    • 11.3.3. UAE Erythropoietin Stimulating Agents Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Application

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Product Launches
  • 13.3. Mergers & Acquisitions

14. Global Erythropoietin Stimulating Agents Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Product

16. PESTLE Analysis

17. Competitive Landscape

  • 17.1. Business Overview
  • 17.2. Company Snapshot
  • 17.3. Products & Services
  • 17.4. Financials (In case of listed companies)
  • 17.5. Recent Developments
  • 17.6. SWOT Analysis
    • 17.6.1. Amgen Inc.
    • 17.6.2. Biocon Limited
    • 17.6.3. Celltrion Inc.
    • 17.6.4. F. Hoffmann-La Roche Ltd
    • 17.6.5. Intas Pharmaceuticals Ltd
    • 17.6.6. Johnson and Johnson
    • 17.6.7. Pfizer Inc.
    • 17.6.8. Teva Pharmaceutical Industries Ltd
    • 17.6.9. Thermo Fisher Scientific
    • 17.6.10. LG Lifesciences, Ltd
    • 17.6.11. Novartis AG(Sandoz)
    • 17.6.12. Panacea Biotec Ltd

18. Strategic Recommendations

19. About Us & Disclaimer